“After surgery, the doctor explained that historically, 1 out of 2 patients experience recurrence of GIST.”1,2

Make an informed decision regarding postsurgical treatment with GLIVEC

Patient characteristics

61 years old

Gastric
KIT+ GIST

Mitotic rate:
>5/50 HPFs

3 months since diagnosis

Original tumour:
3 cm

16% risk
of recurrence3

Patient characteristics

61 years old

Gastric
KIT+ GIST

Mitotic rate:
>5/50 HPFs

3 months since diagnosis

Original tumour:
3 cm

16% risk
of recurrence3

Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed September 21, 2016. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2. Reichardt P, Blay J-Y, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2010;10(2):221-232. 3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.